Qualification of a Noninvasive Magnetic Resonance Imaging Biomarker to Assess Tumor Oxygenation
暂无分享,去创建一个
Bernard Gallez | Julie Magat | J. Magat | B. Gallez | B. Jordan | Marie-Aline Neveu | Florence Colliez | Bénédicte F. Jordan | F. Colliez | Thanh Trang Cao Pham | Marie-Aline Neveu | Marie-Aline C. Neveu | Florence Colliez | T. T. Cao Pham
[1] Kiran Gurung,et al. Mechanisms of tumor resistance to small-molecule vascular disrupting agents: treatment and rationale of combination therapy. , 2013, Journal of the Formosan Medical Association = Taiwan yi zhi.
[2] Fiona A. Stewart,et al. Strategies to improve radiotherapy with targeted drugs , 2011, Nature Reviews Cancer.
[3] C. Baudelet,et al. Effect of anesthesia on the signal intensity in tumors using BOLD-MRI: comparison with flow measurements by Laser Doppler flowmetry and oxygen measurements by luminescence-based probes. , 2004, Magnetic resonance imaging.
[4] S. Beriwal,et al. Upfront treatment of locally advanced cervical cancer with intensity modulated radiation therapy compared to four-field radiation therapy: a cost-effectiveness analysis. , 2013, Gynecologic oncology.
[5] Anwar R. Padhani,et al. Perfusion MRI in the early clinical development of antivascular drugs: decorations or decision making tools? , 2010, European Journal of Nuclear Medicine and Molecular Imaging.
[6] Shingo Matsumoto,et al. Simultaneous imaging of tumor oxygenation and microvascular permeability using Overhauser enhanced MRI , 2009, Proceedings of the National Academy of Sciences.
[7] A. Harris,et al. New strategies for targeting the hypoxic tumour microenvironment in breast cancer. , 2013, Cancer treatment reviews.
[8] C. Hess,et al. Global and health-related quality of life after intensity-modulated radiation therapy for head and neck cancer , 2012, Expert review of anticancer therapy.
[9] Bernard Gallez,et al. Assessment of tumor oxygenation by electron paramagnetic resonance: principles and applications , 2004, NMR in biomedicine.
[10] B. Gallez,et al. Surrogate MR markers of response to chemo- or radiotherapy in association with co-treatments: a retrospective analysis of multi-modal studies. , 2010, Contrast Media & Molecular Imaging.
[11] F. Howe,et al. Evaluation and immunohistochemical qualification of carbogen-induced ΔR₂ as a noninvasive imaging biomarker of improved tumor oxygenation. , 2013, International journal of radiation oncology, biology, physics.
[12] J. Magat,et al. Application of MOBILE (mapping of oxygen by imaging lipids relaxation enhancement) to study variations in tumor oxygenation. , 2013, Advances in experimental medicine and biology.
[13] P. López-Larrubia,et al. Imaging tumor hypoxia by magnetic resonance methods , 2011, NMR in Biomedicine.
[14] B. Rini. The Context of Blood Vessels and Response to VEGF-Targeted Therapy , 2013, Clinical Cancer Research.
[15] A. Harris,et al. Phase I Trial of Combretastatin A4 Phosphate (CA4P) in Combination with Bevacizumab in Patients with Advanced Cancer , 2012, Clinical Cancer Research.
[16] M. Horsman,et al. Induction of hypoxia by vascular disrupting agents and the significance for their combination with radiation therapy , 2013, Acta oncologica.
[17] R. Sharma. Nitroimidazole radiopharmaceuticals in bioimaging: part I: synthesis and imaging applications. , 2011, Current Radiopharmaceuticals.
[18] P Vaupel,et al. Biological consequences of tumor hypoxia. , 2001, Seminars in oncology.
[19] James L Tatum,et al. Hypoxia: Importance in tumor biology, noninvasive measurement by imaging, and value of its measurement in the management of cancer therapy , 2006, International journal of radiation biology.
[20] Uwe Himmelreich,et al. Mapping of oxygen by imaging lipids relaxation enhancement: A potential sensitive endogenous MRI contrast to map variations in tissue oxygenation , 2013, Magnetic resonance in medicine.
[21] Jens Overgaard,et al. Hypoxic radiosensitization: adored and ignored. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[22] H. Schild,et al. Dynamic and simultaneous MR measurement of R1 and R2* changes during respiratory challenges for the assessment of blood and tissue oxygenation , 2013, Magnetic resonance in medicine.
[23] Johannes H Kaanders,et al. Accelerated radiotherapy with carbogen and nicotinamide for laryngeal cancer: results of a phase III randomized trial. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[24] J R Griffiths,et al. Issues in flow and oxygenation dependent contrast (FLOOD) imaging of tumours , 2001, NMR in biomedicine.
[25] S. Ogawa. Brain magnetic resonance imaging with contrast-dependent oxygenation , 1990 .
[26] M. Salgaller. American Association for Cancer Research , 2000, Expert opinion on investigational drugs.
[27] J. Magat,et al. In vivo mapping of tumor oxygen consumption using 19F MRI relaxometry , 2011, NMR in biomedicine.
[28] P C Lauterbur,et al. Paramagnetic contrast agents in nuclear magnetic resonance medical imaging. , 1983, Seminars in nuclear medicine.
[29] Azza B El-Remessy,et al. Angiogenesis inhibitors in cancer therapy: mechanistic perspective on classification and treatment rationales , 2013, British journal of pharmacology.
[30] S. Kaye,et al. Combining Antiangiogenics to Overcome Resistance: Rationale and Clinical Experience , 2012, Clinical Cancer Research.
[31] Geoff J M Parker,et al. Organ‐specific effects of oxygen and carbogen gas inhalation on tissue longitudinal relaxation times , 2007, Magnetic resonance in medicine.
[32] A. Tolcher,et al. Phase I Safety, Pharmacokinetic and Pharmacodynamic Evaluation of the Vascular Disrupting Agent Ombrabulin (AVE8062) in Patients with Advanced Solid Tumors , 2013, Clinical Cancer Research.
[33] L. D. McPhail,et al. Intrinsic susceptibility MR imaging of chemically induced rat mammary tumors: relationship to histologic assessment of hypoxia and fibrosis. , 2010, Radiology.
[34] A. Zygogianni,et al. The Treatment Outcome and Radiation-Induced Toxicity for Patients with Head and Neck Carcinoma in the IMRT Era: A Systematic Review with Dosimetric and Clinical Parameters , 2013, BioMed research international.
[35] P. Lambin,et al. Taking advantage of tumor cell adaptations to hypoxia for developing new tumor markers and treatment strategies , 2009, Journal of enzyme inhibition and medicinal chemistry.
[36] Timothy Solberg,et al. Correlations of noninvasive BOLD and TOLD MRI with pO2 and relevance to tumor radiation response , 2014, Magnetic resonance in medicine.
[37] Claudiu T. Supuran,et al. Interfering with pH regulation in tumours as a therapeutic strategy , 2011, Nature Reviews Drug Discovery.
[38] D. Tank,et al. Brain magnetic resonance imaging with contrast dependent on blood oxygenation. , 1990, Proceedings of the National Academy of Sciences of the United States of America.
[39] Geoff J M Parker,et al. Preliminary study of oxygen-enhanced longitudinal relaxation in MRI: a potential novel biomarker of oxygenation changes in solid tumors. , 2009, International journal of radiation oncology, biology, physics.
[40] J. Bussink,et al. Combretastatin A-4 Phosphate Affects Tumor Vessel Volume and Size Distribution as Assessed Using MRI-Based Vessel Size Imaging , 2012, Clinical Cancer Research.
[41] M. Alber,et al. Imaging oxygenation of human tumours , 2006, European Radiology.
[42] M. Mita,et al. Vascular-disrupting agents in oncology , 2013, Expert opinion on investigational drugs.
[43] Bernard Gallez,et al. How does blood oxygen level‐dependent (BOLD) contrast correlate with oxygen partial pressure (pO2) inside tumors? , 2002, Magnetic resonance in medicine.
[44] G. Jayson,et al. Do Imaging Biomarkers Relate to Outcome in Patients Treated with VEGF Inhibitors? , 2012, Clinical Cancer Research.
[45] H. Cheng,et al. Normal tissue quantitative T1 and T2* MRI relaxation time responses to hypercapnic and hyperoxic gases. , 2011, Academic radiology.
[46] J. Petersen,et al. Imaging hypoxia to improve radiotherapy outcome , 2012, Nature Reviews Clinical Oncology.
[47] V. Grégoire,et al. Thalidomide radiosensitizes tumors through early changes in the tumor microenvironment. , 2005, Clinical cancer research : an official journal of the American Association for Cancer Research.
[48] S. Hahn,et al. Hypoxia imaging markers and applications for radiation treatment planning. , 2012, Seminars in nuclear medicine.
[49] S. Halford,et al. Phase I Clinical and Pharmacokinetic Evaluation of the Vascular-Disrupting Agent OXi4503 in Patients with Advanced Solid Tumors , 2012, Clinical Cancer Research.
[50] J. Waterton,et al. Exploring ΔR2* and ΔR1 as imaging biomarkers of tumor oxygenation , 2013, Journal of magnetic resonance imaging : JMRI.
[51] Ralph P. Mason,et al. Non‐Invasive Physiology and Pharmacology Using 19F Magnetic Resonance , 2008 .